# Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial

Study · id `cardio:ct-nct07073469` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07073469](<https://clinicaltrials.gov/study/NCT07073469>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07073469

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 330 participants.

## Technical summary

Registry record NCT07073469. Randomized; double masking; primary purpose treatment. Start 2025-09-01 (anticipated); primary completion 2027-08-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 330 participants (planned count; ClinicalTrials.gov record NCT07073469, source copy `cardio:ctgov-nct07073469-2025-08-15`, retrieved 2026-10-26)
- Planned start: 2025-09-01 (anticipated) (ClinicalTrials.gov record NCT07073469, source copy `cardio:ctgov-nct07073469-2025-08-15`, retrieved 2026-10-26)
- Primary completion: 2027-08-01 (anticipated) (ClinicalTrials.gov record NCT07073469, source copy `cardio:ctgov-nct07073469-2025-08-15`, retrieved 2026-10-26)
- Completion: 2027-11-01 (anticipated) (ClinicalTrials.gov record NCT07073469, source copy `cardio:ctgov-nct07073469-2025-08-15`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07073469-2025-08-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial
- Condition: Stroke Ischemic
- Intervention (Drug): Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
- Intervention (Other): Standard medical treatment
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Tenecteplase (`cardio:tenecteplase`)
- Registry intervention is a member of this class by a sourced record link: Fibrinolytic (clot-dissolving) drugs (`cardio:fibrinolytic-clot-dissolving-drugs`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: 95a6f51ae12d4ac56e91f3ea60ff0e8646da17272ca7e3e645527d2576b3cd6d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
